 Adverum Biotechnologies Inc NASDAQ: ADVM plans to conduct a Phase 2 trial of ADVM-022 in wet AMD at 2 X 1011 vgeye dose and a new lower 6 X 1010 vgeye dose, with three new enhanced steroid prophylaxis regimens in wet age-related macular degeneration wet AMD. The enhanced steroid prophylaxis regimens include topical, intravitreal IVT, and a combination of systemic and local steroids. 